1-20 of 20
Richard L. Schilsky
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract CT268: Palbociclib (P) in patients (pts) with solid tumors with CCND1 amplification (amp) or mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Ramya Thota, Michael Rothe, Pam K. Mangat, Elizabeth Garrett-Mayer, Tareq Al Baghdadi, Evan Pisick, Olatunji B. Alese, Herbert L. Duvivier, Ajjai S. Alva, Apar Kishor Ganti, Raghava R. Induru, Apostolia M. Tsimberidou, Mehmet Akce, Navid Hafez, Evthokia Hobbs, Andrew Riddle, Margaret von Mehren, Gina N. Grantham, Abigail Gregory, Dominique C. Hinshaw, Susan Halabi, Richard L. Schilsky
Journal: Cancer Research
Cancer Res (2024) 84 (7_Supplement): CT268.
https://doi.org/10.1158/1538-7445.AM2024-CT268
Published: 05 April 2024
View article titled, Abstract CT268: Palbociclib (P) in patients (pts) with solid tumors with <em>CCND1</em> amplification (amp) or mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Journal Articles

Abstract CT267: Temsirolimus (T) in patients (pts) with solid tumors with AKT1/3 amplification (amp) or mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Deepti Behl, Michael Rothe, Pam K. Mangat, Elizabeth Garrett-Mayer, Niklas Mackler, Herbert L. Duvivier, Philip J. Gold, Sapna R. Patel, Regan M. Duffy, Lauren A. Mauro, Eugene R. Ahn, Maria Bell, Carmen J. Calfa, Jean L. Grem, Jens Rueter, Margaret von Mehren, Gina N. Grantham, Abigail Gregory, Dominique C. Hinshaw, Susan Halabi, Richard L. Schilsky
Journal: Cancer Research
Cancer Res (2024) 84 (7_Supplement): CT267.
https://doi.org/10.1158/1538-7445.AM2024-CT267
Published: 05 April 2024
View article titled, Abstract CT267: Temsirolimus (T) in patients (pts) with solid tumors with <em>AKT1/3</em> amplification (amp) or mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Journal Articles

Abstract CT226: Crizotinib (C) in patients (pts) with solid tumors with MET amplification (amp) or mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Kathryn F. Mileham, Michael Rothe, Pam K. Mangat, Elizabeth Garrett-Mayer, Herbert L. Duvivier, Carmen J. Calfa, Carrie L. Dul, Alissa S. Marr, Eugene R. Ahn, Deepti Behl, Michael J. Hall, Inderjit Mehmi, Anu Gaba, Rom Leidner, Mark M. Zalupski, Gina N. Grantham, Abigail Gregory, Susan Halabi, Richard L. Schilsky
Journal: Cancer Research
Cancer Res (2023) 83 (8_Supplement): CT226.
https://doi.org/10.1158/1538-7445.AM2023-CT226
Published: 14 April 2023
View article titled, Abstract CT226: Crizotinib (C) in patients (pts) with solid tumors with <em>MET</em> amplification (amp) or mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Journal Articles

Abstract CT231: Temsirolimus (T) in patients (pts) with solid tumors with PTEN mutation (mut): results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Kristopher Wentzel, Michael Rothe, Pam K. Mangat, Elizabeth Garrett-Mayer, Li Ding, Evan Pisick, Mridula Krishnan, Deepti Behl, Olatunji B. Alese, Carmen J. Calfa, Kathrine A. Cooper, Herbert L. Duvivier, Raghava Reddy Induru, Janet C. Ruzich, Song Zhao, Gina N. Grantham, Abigail Gregory, Susan Halabi, Richard L. Schilsky
Journal: Cancer Research
Cancer Res (2023) 83 (8_Supplement): CT231.
https://doi.org/10.1158/1538-7445.AM2023-CT231
Published: 14 April 2023
View article titled, Abstract CT231: Temsirolimus (T) in patients (pts) with solid tumors with <em>PTEN</em> mutation (mut): results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Journal Articles

Abstract CT110: Olaparib (O) in patients (pts) with solid tumors with ATM mutation or deletion: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Kathryn F. Mileham, Michael Rothe, Pam K. Mangat, Elizabeth Garrett-Mayer, Eddy S. Yang, Olatunji B. Alese, Angela Jain, Herbert L. Duvivier, Phillip Palmbos, Eugene R. Ahn, Jeanny B. Aragon-Ching, Kathleen W. Beekman, Deepti Behl, Funda Meric-Bernstam, Rodolfo Gutierrez, Amy Sanford, Ramya Thota, Michael Zakem, Song Zhao, Raegan O'Lone, Gina N. Grantham, Susan Halabi, Richard L. Schilsky
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): CT110.
https://doi.org/10.1158/1538-7445.AM2022-CT110
Published: 15 June 2022
View article titled, Abstract CT110: Olaparib (O) in patients (pts) with solid tumors with <em>ATM</em> mutation or deletion: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Journal Articles

Abstract 3890: Sequencing of 888 pediatric solid tumors informs precision oncology trial design and data sharing initiatives in pediatric cancer

Suzanne J. Forrest, Hersh Gupta, Abigail Ward, Yvonne Li, Duong Doan, Alyaa Al-Ibraheemi, Sanda Alexandrescu, Pratiti Bandopadhayay, Suzanne Shusterman, Elizabeth A. Mullen, Natalie Collins, Susan N. Chi, Karen D. Wright, Priti Kumari, Tali Mazor, Keith L. Ligon, Priyanka Shivdasani, Phani Davineni, Monica Manam, Richard L. Schilsky, Suanna S. Bruinooge, Jaime M. Guidry Auvil, Ethan Cerami, Barrett J. Rollins, Matthew L. Meyerson, Neal I. Lindeman, Laura MacConaill, Bruce E. Johnson, Andrew D. Cherniack, Alanna J. Church, Katherine A. Janeway
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 3890.
https://doi.org/10.1158/1538-7445.AM2022-3890
Published: 15 June 2022
View article titled, Abstract 3890: Sequencing of 888 pediatric solid tumors informs precision oncology trial design and data sharing initiatives in pediatric cancer
Journal Articles

Abstract CT173: Sunitinib (S) in patients (pts) with metastatic breast cancer (mBC) with FGFR1 mutations or amplifications: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Carmen Calfa, Michael Rothe, Pam K. Mangat, Elizabeth Garrett-Mayer, Eugene Ahn, Keerthi Gogineni, Nitin Rohatgi, Monika L. Burness, Anu Gaba, Omid Hamid, Tareq Albaghdadi, Alison Conlin, Philip Gold, Jordi Rodon, Ramya Thota, Richard L. Schilsky
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): CT173.
https://doi.org/10.1158/1538-7445.AM2021-CT173
Published: 01 July 2021
View article titled, Abstract CT173: Sunitinib (S) in patients (pts) with metastatic breast cancer (mBC) with <em>FGFR1</em> mutations or amplifications: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Journal Articles

Abstract CT135: Cetuximab (C) in patients (Pts) with breast cancer (BC) and non-small cell lung cancer (NSCLC) without reported KRAS, NRAS, BRAF mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Julie Fisher, Elizabeth Garrett-Mayer, Susan Halabi, Pam K. Mangat, Ricardo H. Alvarez, Timothy L. Cannon, Pamela Crilley, Theodore Pollock, Tareq Al Baghdadi, Jared A. Cotta, Andrew L. Rygiel, Kaitlyn R. Antonelli, Samiha Islam, Suanna S. Bruinooge, Richard L. Schilsky
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): CT135.
https://doi.org/10.1158/1538-7445.AM2019-CT135
Published: 01 July 2019
View article titled, Abstract CT135: Cetuximab (C) in patients (Pts) with breast cancer (BC) and non-small cell lung cancer (NSCLC) without reported <em>KRAS, NRAS, BRAF</em> mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Journal Articles

Abstract CT146: Sunitinib (S) in patients (Pts) with metastatic colorectal cancer (mCRC) with FLT-3 alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Ricardo H. Alvarez, Elizabeth Garrett-Mayer, Susan Halabi, Pam K. Mangat, Tareq Al Baghdadi, Eugene R. Ahn, Seungjean Chai, Andrew L. Rygiel, Kaitlyn R. Antonelli, Samiha Islam, Suanna S. Bruinooge, Richard L. Schilsky
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): CT146.
https://doi.org/10.1158/1538-7445.AM2019-CT146
Published: 01 July 2019
View article titled, Abstract CT146: Sunitinib (S) in patients (Pts) with metastatic colorectal cancer (mCRC) with <em>FLT-3</em> alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Journal Articles

Issues around clinical endpoints for registration studies.

Richard L. Schilsky
Journal: Cancer Research
Cancer Res (2004) 64 (7_Supplement): 1313–1314.
Published: 01 April 2004
View article titled, Issues around clinical endpoints for registration studies.
Journal Articles

Phase I and Pharmacokinetic Study of a New Antineoplastic Agent: Pyrazine Diazohydroxide (NSC 361456)

Nicholas J. Vogelzang, Rosemarie Mick, Linda Janisch, Frances Berezin, Richard L. Schilsky, Mark J. Ratain
Journal: Cancer Research
Cancer Res (1994) 54 (1): 114–119.
Published: 01 January 1994
View article titled, Phase I and Pharmacokinetic Study of a New Antineoplastic Agent: Pyrazine Diazohydroxide (NSC 361456)
Open the PDF for Phase I and Pharmacokinetic Study of a New Antineoplastic Agent: Pyrazine Diazohydroxide (NSC 361456) in another window
Journal Articles

Phase I Study of Amonafide Dosing Based on Acetylator Phenotype

Mark J. Ratain, Rosemarie Mick, Frances Berezin, Linda Janisch, Richard L. Schilsky, Nicholas J. Vogelzang, L. Brian Lane
Journal: Cancer Research
Cancer Res (1993) 53 (10): 2304–2308.
Published: 01 May 1993
View article titled, Phase I Study of Amonafide Dosing Based on Acetylator Phenotype
Open the PDF for Phase I Study of Amonafide Dosing Based on Acetylator Phenotype in another window
Journal Articles

Phase I Clinical and Pharmacological Study of Iododeoxyuridine and Bleomycin in Patients with Advanced Cancer

Richard L. Schilsky, Linda Janisch, Frances Berezin, Rosemarie Mick, Nicholas J. Vogelzang, Mark J. Ratain
Journal: Cancer Research
Cancer Res (1993) 53 (6): 1293–1296.
Published: 01 March 1993
View article titled, Phase I Clinical and Pharmacological Study of Iododeoxyuridine and Bleomycin in Patients with Advanced Cancer
Open the PDF for Phase I Clinical and Pharmacological Study of Iododeoxyuridine and Bleomycin in Patients with Advanced Cancer in another window
Journal Articles

Correspondence re: Mark J. Ratain et al., Limited Sampling Models for Amonafide (NSC 308847) Pharmacokinetics. Cancer Res., 48: 4127–4130, 1988—Reply

Mark J. Ratain, Richard L. Schilsky, Alfred E. Staubus
Journal: Cancer Research
Cancer Res (1989) 49 (11): 3139–3140.
Published: 01 June 1989
View article titled, Correspondence re: Mark J. Ratain <em>et al.</em>, Limited Sampling Models for Amonafide (NSC 308847) Pharmacokinetics. Cancer Res., <em>48:</em> 4127–4130, 1988—Reply
Open the PDF for Correspondence re: Mark J. Ratain <em>et al.</em>, Limited Sampling Models for Amonafide (NSC 308847) Pharmacokinetics. Cancer Res., <em>48:</em> 4127–4130, 1988—Reply in another window
Journal Articles

Synergistic Cytotoxicity and DNA Strand Break Formation by Bromodeoxyuridine and Bleomycin in Human Tumor Cells

Stephen P. Ackland, Richard L. Schilsky, Michael A. Beckett, Ralph R. Weichselbaum
Journal: Cancer Research
Cancer Res (1988) 48 (15): 4244–4249.
Published: 01 August 1988
View article titled, Synergistic Cytotoxicity and DNA Strand Break Formation by Bromodeoxyuridine and Bleomycin in Human Tumor Cells
Open the PDF for Synergistic Cytotoxicity and DNA Strand Break Formation by Bromodeoxyuridine and Bleomycin in Human Tumor Cells in another window
Journal Articles

Limited Sampling Models for Amonafide (NSC 308847) Pharmacokinetics

Mark J. Ratain, Alfred E. Staubus, Richard L. Schilsky, Louis Malspeis
Journal: Cancer Research
Cancer Res (1988) 48 (14): 4127–4130.
Published: 01 July 1988
View article titled, Limited Sampling Models for Amonafide (NSC 308847) Pharmacokinetics
Open the PDF for Limited Sampling Models for Amonafide (NSC 308847) Pharmacokinetics in another window
Journal Articles

Phase I Clinical and Pharmacological Study of 72-Hour Continuous Infusion of Etoposide in Patients with Advanced Cancer

Charles L. Bennett, Joseph A. Sinkule, Richard L. Schilsky, Elizabeth Senekjian, Kyung E. Choi
Journal: Cancer Research
Cancer Res (1987) 47 (7): 1952–1956.
Published: 01 April 1987
View article titled, Phase I Clinical and Pharmacological Study of 72-Hour Continuous Infusion of Etoposide in Patients with Advanced Cancer
Open the PDF for Phase I Clinical and Pharmacological Study of 72-Hour Continuous Infusion of Etoposide in Patients with Advanced Cancer in another window
Journal Articles

Correspondence re: M. J. Egorin et al. Human Pharmacokinetics, Excretion, and Metabolism of the Anthracycline Antibiotic Menogaril (7-OMEN, NSC 269148) and Their Correlation with Clinical Toxicities. Cancer Res., 46: 1513–1520, 1986.

Mark J. Ratain, Richard L. Schilsky
Journal: Cancer Research
Cancer Res (1986) 46 (9): 4874.
Published: 01 September 1986
View article titled, Correspondence re: M. J. Egorin <em>et al.</em> Human Pharmacokinetics, Excretion, and Metabolism of the Anthracycline Antibiotic Menogaril (7-OMEN, NSC 269148) and Their Correlation with Clinical Toxicities. Cancer Res., <em>46:</em> 1513–1520, 1986.
Open the PDF for Correspondence re: M. J. Egorin <em>et al.</em> Human Pharmacokinetics, Excretion, and Metabolism of the Anthracycline Antibiotic Menogaril (7-OMEN, NSC 269148) and Their Correlation with Clinical Toxicities. Cancer Res., <em>46:</em> 1513–1520, 1986. in another window
Journal Articles

Phase I Clinical and Pharmacological Study of Thymidine (NSC 21548) and cis-Diamminedichloroplatinum(II) in Patients with Advanced Cancer

Richard L. Schilsky, Kathleen O'Laughlin, Mark J. Ratain
Journal: Cancer Research
Cancer Res (1986) 46 (8): 4184–4188.
Published: 01 August 1986
View article titled, Phase I Clinical and Pharmacological Study of Thymidine (NSC 21548) and <em>cis</em>-Diamminedichloroplatinum(II) in Patients with Advanced Cancer
Open the PDF for Phase I Clinical and Pharmacological Study of Thymidine (NSC 21548) and <em>cis</em>-Diamminedichloroplatinum(II) in Patients with Advanced Cancer in another window
Journal Articles

Phase I Trial and Pharmacokinetics of Aziridinylbenzoquinone (NSC 182986) in Humans

Richard L. Schilsky, James A. Kelley, Daniel C. Ihde, Dianne M. Howser, Rosemarie S. Cordes, Robert C. Young
Journal: Cancer Research
Cancer Res (1982) 42 (4): 1582–1586.
Published: 01 April 1982
View article titled, Phase I Trial and Pharmacokinetics of Aziridinylbenzoquinone (NSC 182986) in Humans
Open the PDF for Phase I Trial and Pharmacokinetics of Aziridinylbenzoquinone (NSC 182986) in Humans in another window